NCT07490769

Levetiracetam Three Times Daily in Epilepsy

Evaluating Efficacy and Tolerability of Three Times Daily Levetiracetam in Epilepsy Patients

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Waad Alkathiri · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to evaluate the efficacy and tolerability of Levetiracetam administered three times daily in patients with epilepsy. The primary objective is to investigate whether orally administered Levetiracetam three times daily dosing is superior in seizure-free days compared to standard twice-daily dosing in patients with epilepsy. Key questions include: * Does LEV improve seizure control, as measured by seizure-free days? * What adverse events or safety concerns are observed with LEV treatment? Participants will receive Levetiracetam administered three times daily during the treatment phase. The study will use a self-matched, pre-post design in which each participant serves as their own control. Baseline seizure activity and safety data will be collected prior to LEV initiation and compared with data obtained during the treatment period. Participants will attend scheduled clinic visits for efficacy and safety evaluations and will maintain a daily diary to record seizure frequency and any treatment-related events.

Conditions

• Epilepsy

Interventions

Type	Name	Description
DRUG	Levetiracetam	Levetiracetam oral (500mg - 1000 mg) tablet three times a day for 12 months

Timeline

• Start date: 2025-10-01
• Primary completion: 2028-12-30
• Completion: 2028-12-30
• First posted: 2026-03-24
• Last updated: 2026-03-24

Locations

1 site across 1 country: Saudi Arabia